
Veracyte (VCYT) Stock Forecast & Price Target
Veracyte (VCYT) Analyst Ratings
Bulls say
Veracyte Inc. demonstrated strong growth in genomic testing volume, reaching 39,107 tests in 4Q24, which marked a 25% increase, notably driven by a record 22,400 urology tests from Decipher, reflecting a remarkable 45% increase. The company's testing revenue also showed robust performance, amounting to $112.2 million, up 24% compared to the previous quarter. Furthermore, the adjusted EBITDA margin improved significantly, rising by 690 basis points year-over-year, with management projecting continued growth to approximately 21.6% for 2025, indicating a positive trajectory for the company’s financial health.
Bears say
Veracyte Inc. is facing a negative outlook primarily due to slower-than-anticipated growth in its core testing offerings, particularly Afirma and Decipher, which may hinder overall revenue growth, projected at only 10-15%. Additionally, despite a decrease in SG&A and R&D expenses improving the non-GAAP operating margin, the decline in revenue per test from $2,894 to $2,868 indicates potential pricing pressure. Furthermore, headwinds related to a possible exit from the VCYT subsidiary may further dampen revenue expectations for 2025, raising concerns about the company’s ability to maintain its strategic focus and execution effectiveness.
This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares